Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 14, 2024
Finance
Data spells money for a quintet of biotechs
NewAmsterdam’s CETP readout leads to week’s largest follow-on
BioCentury | Dec 12, 2024
Data Byte
Candel leads biotech gainers amid wave of data readouts
Prostate cancer data lead to a nearly 70% stock bump; dermatitis data sink Q32 shares
BioCentury | Dec 11, 2024
Product Development
ROR1 shines as the next promising ADC target
Also in BioCentury’s Clinical Report: ASH readouts from Cardiff Oncology, Arcellx and GSK; plus data from NewAmsterdam, AbbVie and more
BioCentury | Mar 6, 2024
Discovery & Translation
Distillery spotlight: new Type II diabetes mechanisms from academia
New targets to drive insulin secretion, islet cell numbers and receptor localization from BioCentury’s survey of the 2023 translational literature
BioCentury | Apr 22, 2022
Discovery & Translation
Genentech and Repare updates; plus an eye gland organoid and more
BioCentury’s roundup of translational news
BioCentury | Jun 4, 2021
Distillery Therapeutics
Inhibiting SHCBP1 to raise trastuzumab sensitivity in gastric cancer
BioCentury | Apr 21, 2021
Product Development
Synthetic lethality’s second wind
The thinking goes beyond the binary paradigm of target plus mutation
BioCentury | Apr 3, 2021
Product Development
Digging beyond the headlines at AACR 2021
Next-wave strategies for KRAS and TIGIT, allogeneic and personalized cell therapies, and targeted protein degraders
BioCentury | Mar 24, 2021
Deals
March 23 Quick Takes: Moulder’s Zenas launches; plus PhoreMost, 1910 Genetics, XyloCor and Catalent
Lonnie Moulder’s cross-border biotech Zenas BioPharma launched Tuesday to develop immune-based therapies. Moulder, the co-founder and CEO of Tesaro Inc., is executive chairman and interim CEO
Items per page:
1 - 10 of 112